Unlike the OPT-CHF trial, in which patients were included in the trial regardless of their baseline UA level, the Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) trial enrolled patients with symptomatic HF and reduced LVEF (≤40%), markedly elevated SUA levels (≥9.5 mg/dL), and relatively well-preserved renal function (eGFR ≥ 20 mL/min). Here, XDH is linked to congestive heart failure.